New Rochelle, NY, January 26, 2015--The promise for using mesenchymal stem cells (MSC) to repair cartilage damage caused by osteoarthritis depends on the MSC being able to attach efficiently to the defective cartilage. A novel laboratory model in which artificially created cartilage lesions and labeled MSC were used to test factors that might improve MSC binding and the effectiveness of future MSC-based therapies is described in BioResearch Open Access, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available on the BioResearch Open Access website.
In the article "ß1 Integrins Mediate Attachment of Mesenchymal Stem Cells to Cartilage Lesions," D. Zwolanek, PhD, and coauthors, University of Veterinary Medicine (Vienna, Austria), University of Cologne Medical Faculty (Germany), University Medical Center Rotterdam (The Netherlands) present the results of experiments using a combination of ex vivo and in vivo model systems of defective cartilage. They studied the effects of serum, plasma hyaluronic acid, and various cell adhesion-related proteins such as integrins on the attachment of MSC to the extracellular matrix of the cartilage.
About the Journal
BioResearch Open Access is a bimonthly peer-reviewed open access journal led by Editor-in-Chief Robert Lanza, MD, Chief Scientific Officer, Advanced Cell Technology, Inc. and Editor Jane Taylor, PhD. The Journal provides a new rapid-publication forum for a broad range of scientific topics including molecular and cellular biology, tissue engineering and biomaterials, bioengineering, regenerative medicine, stem cells, gene therapy, systems biology, genetics, biochemistry, virology, microbiology, and neuroscience. All articles are published within 4 weeks of acceptance and are fully open access and posted on PubMed Central. All journal content is available on the BioResearch Open Access website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many areas of science and biomedical research, including DNA and Cell Biology, Tissue Engineering, Stem Cells and Development, Human Gene Therapy, HGT Methods, and HGT Clinical Development, and AIDS Research and Human Retroviruses. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.